Journal Watch · Journal of Allergy and Clinical Immunology · 2026

Hyperactive STAT1 promotes T<sub>fh</sub>1-cell differentiation to trigger autoimmunity.

These findings imply that proper regulation of STAT1 activity within a reasonable magnitude is crucial for ensuring optimal host-protective humoral immunity, and that IFN-γ neutralization may be a promising treatment option for patients with STAT1 GOF and other related autoimmune diseases.

Chen R, Chen X, Yang J et al.Journal of Allergy and Clinical Immunology3 min readPharma relevance 65/100

DOI: 10.1016/j.jaci.2026.08.030PMID: 42815782Study type: preclinical (animal / model) study

TL;DR

These findings imply that proper regulation of STAT1 activity within a reasonable magnitude is crucial for ensuring optimal host-protective humoral immunity, and that IFN-γ neutralization may be a promising treatment option for patients with STAT1 GOF and other related autoimmune diseases.

Key findings

  • IFN-γ neutralization reduced autoimmune cellular responses and autoantibody levels in mutant mice.<h4>Conclusions</h4>STAT1 GOF promotes aberrant T<sub>fh</sub>1 differentiation to drive autoimmunity and dysregulated humoral responses.
  • These findings imply that proper regulation of STAT1 activity within a reasonable magnitude is crucial for ensuring optimal host-protective humoral immunity, and that IFN-γ neutralization may be a promising treatment option for patients with STAT1 GOF and other related autoimmune diseases.

What they did

Furthermore, Janus kinase inhibition and IFN-γ blockade were evaluated in vivo.<h4>Results</h4>Patients with STAT1 GOF showed a bias in cT<sub>fh</sub> cells toward a CXCR3<sup>+</sup> T<sub>fh</sub>1-like phenotype. In Stat1-GOF mice, excessive STAT1 activation promoted T<sub>fh</sub> differentiation, enhanced germinal center formation, and disturbed T-cell-dependent humoral responses, with immunoglobulin class switching skewed toward IgG2. STAT1 GOF directly targeted T<sub>fh</sub>- and T<sub>H</sub>1-associated genes and drove the development of IFN-γ-producing T<sub>fh</sub>1 cells, which was accompanied by autoantibody production and autoimmune manifestations.

Full abstract (original)

Background: <h4>Background</h4>Heterozygous gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) cause an inborn error of immunity characterized by immune dysregulation, recurrent infections, and various autoimmune manifestations. However, the precise pathogenic mechanism by which STAT1 GOF contributes to autoimmunity remains elusive.<h4>Objective</h4>We sought to determine whether and how STAT1 GOF affects T<sub>fh</sub>-cell differentiation and autoimmune pathogenesis.<h4>Methods</h4>Using Stat1-GOF (T385M) mice, we analyzed the effects of STAT1 GOF on the T<sub>fh</sub> differentiation and germinal center responses on various immune challenging. CUT&Tag and transcriptomic analyses were integrated to dissect how STAT1 GOF contributes to autoimmunity.

What they did: Furthermore, Janus kinase inhibition and IFN-γ blockade were evaluated in vivo.<h4>Results</h4>Patients with STAT1 GOF showed a bias in cT<sub>fh</sub> cells toward a CXCR3<sup>+</sup> T<sub>fh</sub>1-like phenotype. In Stat1-GOF mice, excessive STAT1 activation promoted T<sub>fh</sub> differentiation, enhanced germinal center formation, and disturbed T-cell-dependent humoral responses, with immunoglobulin class switching skewed toward IgG2. STAT1 GOF directly targeted T<sub>fh</sub>- and T<sub>H</sub>1-associated genes and drove the development of IFN-γ-producing T<sub>fh</sub>1 cells, which was accompanied by autoantibody production and autoimmune manifestations.

Results & conclusions: IFN-γ neutralization reduced autoimmune cellular responses and autoantibody levels in mutant mice.<h4>Conclusions</h4>STAT1 GOF promotes aberrant T<sub>fh</sub>1 differentiation to drive autoimmunity and dysregulated humoral responses. These findings imply that proper regulation of STAT1 activity within a reasonable magnitude is crucial for ensuring optimal host-protective humoral immunity, and that IFN-γ neutralization may be a promising treatment option for patients with STAT1 GOF and other related autoimmune diseases.

Abstract © the authors / Journal of Allergy and Clinical Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jaci.2026.08.030 · PubMed 42815782.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Journal of Allergy and Clinical Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Allergy and Clinical Immunology study find?

These findings imply that proper regulation of STAT1 activity within a reasonable magnitude is crucial for ensuring optimal host-protective humoral immunity, and that IFN-γ neutralization may be a promising treatment option for patients with STAT1 GOF and other related autoimmune diseases.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Allergy and Clinical Immunology in 2026. Furthermore, Janus kinase inhibition and IFN-γ blockade were evaluated in vivo.<h4>Results</h4>Patients with STAT1 GOF showed a bias in cT<sub>fh</sub> cells toward a CXCR3<sup>+</sup> T<sub>fh</sub>1-like phenotype.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jaci.2026.08.030. PubMed ID: 42815782. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Chen R, Chen X, Yang J et al.. Hyperactive STAT1 promotes T&lt;sub&gt;fh&lt;/sub&gt;1-cell differentiation to trigger autoimmunity.. Journal of Allergy and Clinical Immunology (2026). DOI: 10.1016/j.jaci.2026.08.030.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/hyperactive-stat1-promotes-t-lt-sub-gt-fh-lt-sub-gt-1-cell-differentiati-608030/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides